Connect with us
Advertisement

News

Global Castration-Resistant Prostate Cancer (CRPC) Market

Published

on

Advertisement

SEATTLE, July 20, 2021 (GLOBE NEWSWIRE) — According to Coherent Market Insights, the global market for castration-resistant prostate cancer is estimated to be US$9.5 billion in 2021 and is expected to grow at a CAGR of . show 8.2% during the forecast period (2021-2028).

Advertisement

Key trends and analysis of the global Castration-resistant prostate cancer Market:
Watch Free Movies and TV shows Apps

🎬📺 Free Movies and Free TV Shows! 🎭🎬

Major trends in the market include the increasing number of prostate cancer cases, increasing number of product launches and increasing research and development activities.

The increasing prevalence of prostate cancer is expected to drive the growth of the global castration-resistant prostate cancer market over the forecast period. For example, according to the Cancer Research UK report 2018, prostate cancer is the most common cancer in men and more than 47,500 men have been diagnosed with prostate cancer, accounting for 129 men a day, and the death rate was over 11,500 men in the UK.

The increasing number of product approvals and launches is expected to fuel the growth of the global castration-resistant prostate cancer market. For example, on May 15, 2020, Clovis Oncology Inc., a biopharmaceutical company, announced that the U.S. Food and Drugs Administration (FDA) has approved Rubraca tablets (rucaparib) for the treatment of adult patients with a deleterious BRCA mutation (BReast CANcer). gene)-associated metastatic castration-resistant prostate cancer (mCRPC).

Advertisement
Advertisement
unnamed
Advertisement

Request a sample copy of this report @ https://www.coherentmarketinsights.com/insight/request-sample/4529

Moreover, increasing research and development activities for the treatment of castration-resistant prostate cancer are expected to drive the growth of the global castration-resistant prostate cancer market. For example, on May 29, 2020, Pfizer Inc., a multinational pharmaceutical company, and Astellas Pharma Inc., a Tokyo-based company in collaboration, announced the final results of the overall survival analysis (OS) of the Phase 3 PROSPER trial. The final PROSPER results showed that XTANDI (enzalutamide) significantly prolonged overall survival in men with non-metastatic castration-resistant prostate cancer (nmCRPC).

Main market takeaways:

The increasing research and development activities, soaring product launches and approvals, inorganic activities such as collaborations, acquisitions and others are expected to drive the growth of the global castration-resistant prostate cancer market over the forecast period. For example, on April 28, 2021, ESSA Pharma Inc., a clinical-stage pharmaceutical company, announced an agreement with Bayer AG, a multinational pharmaceutical and life sciences company. Under the agreement, EPI-7386, ESSA’s lead product candidate, is to be tested in combination with Bayer’s darolutamide in patients with metastatic castration-resistant prostate cancer (‘mCRPC’).

Competitive landscape:

Major players in the global castration-resistant prostate cancer market include Sanofi, Johnson & Johnson Services Inc., Pfizer Inc., Astellas Pharma Inc., Bayer AG, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis International AG, Eli Lilly & Company, and Astra Zeneca plc.

Advertisement

Buy this research report now @ https://www.coherentmarketinsights.com/insight/buy-now/4529

Market share:

  • Global Castration Resistant Prostate Cancer Market Segment By Type:
    • Hormonal therapy
    • Immunotherapy
    • Chemotherapy
  • Global Castration-Resistant Prostate Cancer Market Segment By Drug Class:
    • antineoplastic
    • Non-Steroidal Anti-Androgen
    • Corticosteroids
    • Microtubule Inhibitor
    • others
  • Global Castration-Resistant Prostate Cancer Market, by Route of Administration:
  • Global Castration Resistant Prostate Cancer Market by Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Castration-Resistant Prostate Cancer Market Segment By Regions: Introduction
    • North America
    • Latin America
      • In order by country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • In order by country:
        • UK
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
    • Asia-Pacific
      • In order by country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia-Pacific
    • Middle East
      • In order by country:
        • GCC
        • Israel
        • Rest of the Middle East
    • Africa
      • By country/region:
        • South Africa
        • Central Africa
        • North-Africa

Related Market Information Reports:

Cancer Biology Market, by Product (Monoclonal Antibodies, Cytokine-based Immunotherapy, Cancer Vaccines, CAR-T Cell Therapy, and Immune Checkpoint Inhibitors), by Application (Non-Small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer , gastric cancer and others), by distribution channel (hospitals, clinics and others) and by region (North America, Latin America, Europe, Middle East, Asia-Pacific and Africa) – Analysis of size, share, prospects and opportunities, 2020 – 2027

Read more: https://www.coherentmarketinsights.com/ongoing-insight/cancer-biologics-market-4145

North America and Europe Minimally Invasive Prostate Cancer Surgery Market, by product type (hand (resectoscope, linear cutter, insufflators, curved stapler, endoscopic trocars, prostate retractor, cryoablation device, others), monitoring and visualization (cameras and video assist, endoscopic trocars) with optical display), powered (electrosurgical unit, lasers)), by application (laparoscopy, robotic surgery, brachytherapy, cryosurgery), and by region (North America, Europe) – Analysis of Size, Share, Prospects and Opportunities, 2020 – 2027

Advertisement

Read more: https://www.coherentmarketinsights.com/market-insight/north-america-and-europe-minimally-invasive-prostate-cancer-surgery-market-4079

About us:

Cohesive Market Insights is a global market intelligence and advisory organization focused on helping our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with a sales office at Global Financial Capital in the US and sales advisors in the UK and Japan. Our customer base includes players from various business industries in more than 57 countries around the world.

Follow us: LinkedIn | Twitter

Global Castration-Resistant Prostate Cancer (CRPC) Market

The post Global Castration-Resistant Prostate Cancer (CRPC) Market appeared first on Notesradar.

Advertisement
Advertisement
Advertisement

Trending